Supplementary Material

A



B



Figure S1. TGF-β2 and TGF-β3 inhibit the growth of PDL-derived EPC-like fibroblastic cells. SCDC2 cells were treated with TGF-β2 (*A*) or -β3 (*B*) at the indicated doses for 3 days, and cell growth was evaluated using the alamarBlue assay as described in Materials and Methods. alamarBlue working solution [10% alamarBlue (AbD Serotec, Oxon, UK) in Ham's F-12] was added to each well, and the culture was incubated at 37°C in 5% CO_2 for 1.5 h. Some of the wells were treated with the TGF-β receptor inhibitor SB-431542 (10 μM) and p38 MAPK inhibitor SB 203580 (30 μM), which were added to the culture 30 min before the TGF-β administration. Absorbance was measured using a microplate reader, with 570 nm and 600 nm wavelengths for reduced and oxidized forms of the reagent, respectively. The data are presented as mean ± SD (n = 7). *P <0.05, **P <0.02, and ***P <0.01 were considered significant.



Figure S2. TGF-β2 and TGF-β3 induce the expression of SMC markers (α-SMA, h1-calponin) but suppress the expression of EC marker (Tie-2) in PDL-derived EPC-like fibroblastic cells.

SCDC2 cells were cultured for 3 days in growth medium supplemented with 5% FBS in the presence of the indicated concentrations of TGF-β2 (*A*) or -β3 (*B*). Some of the cells were treated with the TGF-β receptor inhibitor SB-431542 (10 μM), which was added to the culture 30 min before the TGF-β administration. The relative mRNA expression levels of α-SMA, h1-calponin and Tie-2 in the cells were analyzed by qRT-PCR as described in Materials and Methods. Data represent the mean ± SD (n = 3). *P <0.05, **P <0.02, and ***P <0.01 were considered significant.